Premium
Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation
Author(s) -
Ciurea Stefan O.,
Sadegi Barry,
Wilbur Andrew,
AlagiozianAngelova Victoria,
Gaitonde Sujata,
Dobogai Lisa C.,
Akard Luke P.,
Hoffman Ronald,
Rondelli Damiano
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07010.x
Subject(s) - myelofibrosis , medicine , splenectomy , transplantation , hematopoietic stem cell transplantation , stem cell , haematopoiesis , extramedullary hematopoiesis , spleen , gastroenterology , bone marrow , biology , genetics
Summary Changes in spleen size postallogeneic haematopoietic stem cell transplantation (HSCT) in patients with primary myelofibrosis have been poorly characterized. We analysed 10 patients with myelofibrosis and splenomegaly following a reduced‐intensity allogeneic HSCT. All patients fully engrafted donor cells including five patients with extensive splenomegaly. Extensive splenomegaly was associated with a prolonged time to neutrophil and platelet recovery. In all 10 patients, a progressive reduction of splenomegaly was documented within 12 months post‐transplant and paralleled the reduction of marrow fibrosis. These findings suggest that myelofibrosis patients with extensive splenomegaly may proceed with allogeneic HSCT without prior splenectomy.